ライフサイエンスコーパス: MyD88

1 differentiation primary response protein 88 (MYD88).

2 myeloid differentiation primary response 88 (MyD88).

3 and TRAF6 but not the IL-1R/TLR-IRAK adaptor MyD88.

4 ST2 signals through the adapter protein MyD88.

5 mutations altering the BCR subunit CD79B and MYD88.

6 nteraction of MAL with its downstream target MyD88.

7 with the human TLR adapter proteins MAL and MYD88.

8 ptor interacts with mTOR via the TLR adapter MyD88.

9 V control in hematological cells, similar to MyD88.

10 ammatory cytokines via the signaling adaptor MyD88.

11 GABA(A) receptor alpha2 subunits (~60%) and MyD88 (~40%).

12 aldenstrom macroglobulinemia (WM), including MYD88 (95%-97%), CXCR4 (30%-40%), ARID1A (17%), and CD79

13 ignals via a canonical pathway involving the MyD88 adapter and the interleukin-1 receptor-associated

14 ion of mature RPMs through activation of the MyD88 adaptor protein and ERK1/2 kinases downstream of t

15 ignals via the appropriate receptors and the MyD88 adaptor protein.

16 IL-17B production through Toll-like receptor-Myd88 adaptor signaling.

17 MyD88 adaptor-like (Mal) protein is the most polymorphic

18 he Toll-interleukin-1 receptor (TIR) adaptor Myd88 adaptor-like (Mal), TNF receptor-associated factor

19 al signature (enhanced IL-1beta, CD14, Mmp9, Myd88, Ager, and Stat3) that was dependent on IL-6.

20 on factor, and 4) NF-kappaB likely regulates MyD88 alternative pre-mRNA splicing per se rather than r

21 B cells were used in the single-cell IGH and MYD88 analyses.

22 vide an explanation for the co-occurrence of MYD88 and CD79B mutations in lymphomas.

23 tivating mutations in the signaling adaptors MYD88 and CD79B, and immune evasion through mutation of

24 The mutation status of both MYD88 and CXCR4 can be used for a precision-guided treat

25 e to major response, and PFS are impacted by MYD88 and CXCR4 mutation status.

26 Transcription is affected by MYD88 and CXCR4 mutations and includes overexpression of

27 The discovery of MYD88 and CXCR4 mutations in WM has facilitated rational

28 Responses were impacted by mutated (Mut) MYD88 and CXCR4 status.

29 To investigate the roles of Myd88 and Fcer1g in non-B cells, we transferred anti-sel

30 MyD88 and FcR common gamma-chain (Fcer1g, FcRgamma) elic

31 ment was dependent on CD40L, indicating that Myd88 and FcRgamma, presumably on myeloid APCs, were req

32 osome 6q are common in patients with mutated MYD88 and include genes that modulate NFKB, BCL2, Bruton

33 Our data show that in pericytes, MyD88 and IRAK4 are key regulators of 2 major injury res

34 at is dependent on the TLR signaling adaptor MyD88 and its downstream kinase IL-1R-associated kinase

35 ed ABC-associated mutations in genes such as MYD88 and PIM1.

36 at steady state via direct interaction with MyD88 and PIP5K.

37 Thus, MyD88 and STING contribute to MCMV control in distinct c

38 natural killer cytotoxicity was dependent on MyD88 and STING.

39 (AAV)2/1-carrying truncated gRNAs targeting Myd88 and the MS2-HP1a-KRAB cassette.

40 at CO inhibited the interaction of TLR4 with MyD88 and TIR domain-containing adapter-inducing IFN-bet

41 sent from mice deficient in the TLR adaptors MyD88 and TRIF and required IFNgamma secretion by lamina

42 tor signalling through the adaptor molecules MyD88 and TRIF in turn mediates efficient activation of

43 Signaling through the adaptor proteins MyD88 and TRIF resulted in activation of ATP-citrate lya

44 ion is mediated through the adaptor proteins MyD88 and TRIF, and this is inhibited by MK2.

45 TLR4 signalling through the MyD88 and TRIF-dependent pathways initiates translocatio

46 cytosis of TLR4 and NOX2, independently from MyD88 and TRIF.

47 in lipid A endotoxicity mediated through the MyD88 and TRIF/TRAM arms of the TLR4-signaling pathway w

48 the BTK inhibitor ibrutinib, are affected by MYD88 and/or CXCR4 mutation status.

49 mice deficient in Tlr4 (Tlr4(-/-) ), Myd88 (Myd88 (-/-)), and myeloid-specific Tlr4 (Tlr4(f/f)Lyz2(C

50 suggest increased P. aeruginosa adhesion to MyD88(-/-) and blotted corneas is not due to reduction i

51 Like Myd88(-/-) and Irf3(-/-) mice, Rel(C307X) mice were susc

52 for pathogen-associated molecular patterns, MyD88(-/-) and STING(-/-) mice had 1,350 and 80 copies o

53 upregulated expression of TLR4, its adaptor MyD88, and coreceptors CD14 and MD2.

54 urface glycosylation requires IL-1R, but not MyD88, and is not sufficient to prevent bacterial bindin

55 ytokine IL-34 and Toll-like receptor adaptor MyD88, and occurs in coordination with neutrophils.

56 eta, and activation of this pathway involves MYD88- and NOD2-dependent sensing of the microbiota.

57 , 2) MyD88 splicing is regulated by both the MyD88- and TRIF-dependent arms of the TLR signaling path

58 Using mutated MYD88 as a tumor marker, BTK(Cys481) mutations were subc

59 horts, we were powered to identify wild type MYD88 as an independent predictor of progression (hazard

60 C458S] mutant, we identify IRAK1, IRAK2, and MyD88 as physiological substrates of the HOIL-1 E3 ligas

61 m regulators (INFgamma, IL-1beta, NF-kappaB, MYD88) associated with inflammation.

62 Inhibition of MyD88 attenuates the LLC-induced activation of the UPR i

63 e a detectable Myddosome formation, the TLR4/MyD88 axis was important for phosphorylation of p38 and

64 ive molecular subtypes were resolved, termed MYD88, BCL2, SOCS1/SGK1, TET2/SGK1, and NOTCH2, along wi

65 uencing revealed frequent mutations in TP53, MYD88, BCOR, MYC, SF3B1, SETD2, CHD2, CXCR4, and BCLAF1.

66 interaction by rapamycin, truncation of the MyD88-binding domain of TACI, or B-cell-conditional mTOR

67 This response requires Myd88 but not TRIF or STING.

68 ts were highly dependent on B-cell-intrinsic MyD88, but not Trif expression.

69 group Ags, while blocking both BCRs and TLR-MyD88 by using Bruton's tyrosine kinase inhibitor and hi

70 hat CRISPR-mediated repression of endogenous Myd88 can effectively modulate the host immune response

71 absence of the adjuvant effect in vaccinated MyD88(-/-)Cardif(-/-) mice, which are devoid of TLR (wit

72 Transcriptome analysis of sorted MyD88(-/-) CD4 T cells from the intestine 10 d post-HCT

73 This protection was entirely driven by MyD88(-/-) CD4 T cells.

74 emporal pattern was absent (IL-1beta, CXCL1, Myd88, Cd4) or reversed (C3) in the respective tissues o

75 ped a fusion protein by linking CD8alpha and MyD88 (CD8alpha:MyD88) to enhance CD8(+) T-cell response

76 nscription 3 (STAT3) signaling was higher in Myd88(-/-) compared to wild type (WT) mice, indicating a

77 Transplanting donor MyD88(-/-) conventional T cells (Tcons) with wild-type (

78 investigation include therapeutics targeting MYD88, CXCR4, and BCL2 signaling.

79 ld type (WT) mice, indicating a link between MyD88 deficiency and STAT3 activation in response to H.

80 Thereby, MyD88 deficiency results in accelerated and aggravated g

81 7, or TLR9 deficiency and cell type-specific MyD88 deficiency to study the functional correlation bet

82 e responses are similar to those of TLR4 and MyD88 deficient mice in these models and confirm that GS

83 hether the exacerbated pathology observed in MyD88-deficient (Myd88(-/-)) mice was associated with ab

84 TLR2-, TLR4-, MyD88-deficient and WT BALB/c mice were intratracheally

85 educed generation of TNF-alpha in lesions of MyD88-deficient animals, a pro-inflammatory molecule tha

86 MyD88-deficient mice and zebrafish were not only impaire

87 E1 is safe in the severely immunocompromised MyD88-deficient mice, whereas virulent B. pertussis caus

88 Unlike most IRAK-4- or MyD88-deficient patients, he did not suffer from invasiv

89 actic treatments in healthy immunocompetent, MyD88-deficient, lymphocyte-deficient, and neutrophil-de

90 e later hyperinflammatory phase is partially MyD88 dependent and ineffective in the lungs but control

91 nuclear factor kappa B pathways in MDSCs was MyD88 dependent.

92 id differentiation primary response gene 88 (MyD88)-dependent fashion.

93 ifferentiation into CD5(dim) (B-1b) cells in MyD88-dependent and CNI-resistant manner.

94 This TAS response was MyD88-dependent and sufficient to directly suppress both

95 In the early phase, low-level MyD88-dependent chemokine expression limits initial grow

96 inistered 24 hours after radiation and shows MyD88-dependent function.

97 promotes skin inflammation involving IL-36R/MyD88-dependent IL-17 T cell responses.

98 chanistically, commensal bacteria stimulated Myd88-dependent IL-1beta and IL-23 production from myelo

99 d translocation of endotoxin, initiating TLR/MyD88-dependent inflammation in Cox2 KO but not WT mice.

100 of the transcription factor ROR-gammat in a MyD88-dependent manner, which was deficient in FA infant

101 ges and release inflammatory cytokines in an MyD88-dependent manner, with antistimulatory CPS activat

102 ited by TRAM through activation of TLR4 in a MyD88-dependent manner.

103 pillomaviruses involving the activation of a MyD88-dependent pathway and IL-1 receptor signaling, con

104 ese findings suggest that disruption of this MyD88-dependent pathway in pericytes might be a potentia

105 due to TLR4-dependent signaling through the MyD88-dependent pathway of the innate immune response, a

106 controlled by inputs from the TCR and a TLR2-MyD88-dependent PI3K signaling pathway.

107 This process is driven by IL-1/MyD88-dependent production of G-CSF.

108 AP stimulates endosomal TLRs, resulting in a Myd88-dependent production of type I IFN.

109 cells via a novel pathway, that antagonized MyD88-dependent quiescence, and engaged Weckle and Yorki

110 is not, and this is likely due to the early MyD88-dependent recognition of ligands other than profil

111 nfection, mycobacteria rely on PDIM to evade Myd88-dependent recruitment of microbicidal monocytes wh

112 strates equipotent activity against multiple MyD88-dependent responses both in vitro and in vivo.

113 l kinase that phosphorylates MyD88, promoted MyD88-dependent signaling and mediates dermatosis in Ptp

114 binds directly to TLR2 and TLR4 to activate MyD88-dependent signaling, cytokine expression and neutr

115 the cell surface to elicit inflammation via MyD88-dependent signaling.

116 of danger-associated molecular patterns and MyD88-dependent signaling.

117 ally controlled, but resulted from sustained MYD88-dependent signalling induced by commensal bacteria

118 us S. aureus exposure to mouse skin promoted MyD88-dependent skin inflammation initiated by IL-36, bu

119 it homologous to that which drives canonical MYD88-dependent TLR signaling in contemporary mammalian

120 Thus, talin1 regulates MyD88-dependent TLR signaling pathways in DCs through a

121 MyD88-dependent TLR stimulation in B-1b cells enhanced d

122 results define a role for myeloid-specific, MyD88-dependent TLR4 signaling in the inflammatory respo

123 ent Langerhans cell (LC) migration, but also MyD88-dependent Toll-like receptor (TLR)-stimulated DC a

124 acid deoxycholic acid, can restore pDC- and MyD88-dependent type I IFN responses to restrict systemi

125 inflammatory cytokine production was through MyD88-dependent, TRIF-independent, TLR4-induced events.

126 function against Pseudomonas aeruginosa was MyD88-dependent.

127 to phosphoinositide metabolism and inhibits MyD88-directed signal transduction.

128 r these findings indicate a central role for MyD88 during the biphasic inflammatory response to pulmo

129 CD8alpha:MyD88-expressing T cells improved antitumor responses in

130 t this strategy can efficiently downregulate Myd88 expression in lung, blood and bone marrow of Cas9

131 production was dependent on B cell-intrinsic MyD88 expression, suggesting an important role for TLR s

132 via delayed kinetics of Mal interaction with MyD88 following LPS stimulation.

133 ) the induction of the alternatively spliced MyD88 form is due to alternative pre-mRNA splicing and n

134 emergency hematopoiesis and identify an IL-1/MyD88/G-CSF-dependent pathway as the key regulator of em

135 Myeloid differentiation primary response 88 (Myd88) gene in vitro and in vivo.

136 myeloid differentiation primary response 88 (MYD88) gene.

137 Our results indicate that, in the absence of MyD88, H. felis infection enhances the activation of non

138 MyD88 has been shown to be a direct target of miR-3085-3

139 Why TLR9 represses disease while TLR7 and MyD88 have the opposite effect remains undefined.

140 can circumvent the loss of IRAK1, IRAK4, and MYD88; however, the deletion clones are deficient in int

141 Deletion of MyD88 impairs fusion of myoblasts without affecting thei

142 lpha (IL-1alpha) signaling through IL-1R and MyD88 in both stromal and immune cells drive inflammatio

143 ession of a non-self-reactive BCR or loss of MyD88 in Ikaros-deficient B cells.

144 Specific ablation of MyD88 in pericytes or pharmacological inhibition of MyD8

145 The role of MyD88 in T cells during aGVHD has yet to be elucidated.

146 We found that knocking out MyD88 in the donor T cells protected against aGVHD indep

147 myeloid differentiation primary response 88 (MyD88) in pneumonic plague.

148 oles of toll-like receptor (TLR) 2, TLR4 and MyD88, in exacerbation of allergen-induced lung eosinoph

149 produced IFN-I in a cGAS-STING-dependent and MyD88-independent manner, while we confirmed plasmacytoi

150 wnstream of TLR4, which can also activate an MyD88-independent pathway.

151 86126 failed to inhibit assays downstream of MyD88-independent receptors, including the TNF receptor

152 id differentiation primary response gene 88 (MyD88), indicating that the adjuvants function in vivo v

153 Targeted ablation of MyD88 inhibits the loss of skeletal muscle mass and stre

154 We show that DMF blocks IRAK4-MyD88 interactions and IRAK4-mediated cytokine productio

155 myeloid differentiation primary response 88 (MYD88)/interleukin-1 receptor associated kinase (IRAK) p

156 differentiation primary response protein 88 (MyD88)-IRAK-dependent signaling axis.

157 receptor domain containing adaptor protein)-MyD88-IRAK (interleukin-1 receptor-associated kinase)1/4

158 hat, unlike B cell receptor (BCR) signaling, MYD88/IRAK signaling is constitutively active in PEL, bu

159 Here, we report an unconventional IL-1R-MyD88-IRAK2-PHB/OPA1 signaling axis that reprograms mito

160 Deletion of either MYD88, IRAK4, or IRAK1 abolished interleukin-1 beta (IL-

161 ese findings confirm that signalling through MyD88 is the primary driver for LPS-dependent NF-kappaB

162 ginates from the cell surface and depends on MyD88; it involves combined activation of the transcript

163 In addition, MyD88(-/-) joint inflammatory cytokine levels on day 3 a

164 Subsequently, swelling of MyD88(-/-) joints surpassed WT joint swelling, and resol

165 Finally, we found that TLR4 and MYD88 knockdown inhibited PTX3-induced melanoma cell mig

166 However, at later time points, MyD88 knockdown remains inhibitory and so other function

167 rated in experiments with TLR4-deficient and MyD88-knockout mice.

168 n with IRAK1 increased NF-kappaB activity in MYD88 KO, IRAK1 KO, and IRAK4 KO cells even in the absen

169 The MYD88 L265P mutant results in the activation of interleu

170 g checkpoint against B cell dysregulation by MYD88(L265P) and provide an explanation for the co-occur

171 Conversely, B cells expressing MYD88(L265P) decreased surface IgM coupled with accumula

172 IRAK4 inhibition in the treatment of mutant MYD88(L265P) diffuse large B-cell lymphoma (DLBCL).

173 The frequencies of the dominant IGH and MYD88(L265P) mutation and the genome-wide copy number ab

174 B-cell genomic characterization of the IGH, MYD88(L265P) mutation, and copy number profile enables V

175 encies of dominant IGH (88.8% +/- 13.2%) and MYD88(L265P) mutations (35.0% +/- 31.3%) were detected i

176 ere we analyze the consequences of CD79B and MYD88(L265P) mutations individually and combined in norm

177 ature B cell malignancies, especially in the MYD88(L265P), CD79B mutant (MCD) genetic subtype of diff

178 5.9% +/- 13.4% and 1.5% +/- 2.6% for IGH and MYD88(L265P), respectively).

179 n of SYK, ERK, and AKT and the other through MYD88 leading to activation of NF-kappaB.

180 NF-kappaB pathway genes (CARD11, CD79B, and MYD88), losses of 17p13 and gains of chromosome 7, 11q12

181 We conclude that alternative splicing of MyD88 may provide a sensitive mechanism that ensures rob

182 llectively, our results demonstrate that TLR/MyD88-mediated activation of XBP1 causes skeletal muscle

183 TLR2-deficient (Tlr2 (-/-)) and Myd88 (-/-) mice express lower EC cell numbers and 5-HT

184 n was significantly reduced in TLR4(-/-) and Myd88(-/-) mice and following pretreatment with a NF-kap

185 Surprisingly, corneas from MyD88(-/-) mice displayed similar GalNAz labeling to wil

186 nlike IL-12p40(-/-) and IFN-gamma(-/-) mice, MyD88(-/-) mice survived N. caninum infections at the do

187 ke helicase signaling, whereas in vaccinated MyD88(-/-) mice the adjuvant effect was reduced.

188 Nevertheless, Myd88(-/-) mice were more sensitive to lethality from se

189 rial measures of parasite burden showed that MyD88(-/-) mice were more susceptible to N. caninum infe

190 We show that pulmonary challenge of Myd88(-/-) mice with wild-type (WT) Y. pestis results in

191 In MyD88(-/-) mice, this pro-inflammatory mediator-inducing

192 ressed in gene-deficient mice, especially in MyD88(-/-) mice.

193 and IL-12p40 production was not detected in MyD88(-/-) mice.

194 bated pathology observed in MyD88-deficient (Myd88(-/-)) mice was associated with aberrant activation

195 studies indicated that the adaptor molecule, MyD88, might be important for this change.

196 Patients with MYD88(Mut), wild-type (WT) CXCR4 showed higher major (97

197 d 38% for those with MYD88(Mut)CXCR4(WT) and MYD88(Mut)CXCR4(Mut) WM, respectively (P = .02).

198 v 4.7 months; P = .02) versus patients with MYD88(Mut)CXCR4(Mut).

199 reached, and was 70% and 38% for those with MYD88(Mut)CXCR4(WT) and MYD88(Mut)CXCR4(Mut) WM, respect

200 d phenotypic features of tumor cells from 35 MYD88-mutated WM patients in relation to normal plasma a

201 ene addiction in cell lines with TCF3/ID3 or MYD88 mutation.

202 CD79B and MYD88 mutations are frequently and simultaneously detect

203 ding patients having PCNSL with CD79B and/or MYD88 mutations, and 86% of evaluable patients achieved

204 we used mice deficient in Tlr4 (Tlr4(-/-) ), Myd88 (Myd88 (-/-)), and myeloid-specific Tlr4 (Tlr4(f/f

205 platelets from mice with genetic deletion of MyD88 (myeloid differentiation factor 88) or TLRs (Toll-

206 ages promote monocyte recruitment through an MYD88 (myeloid differentiation primary response 88)-depe

207 motif-containing protein) is a member of the MyD88 (myeloid differentiation primary response gene 88)

208 esion if it lacks the innate defense protein MyD88 (myeloid differentiation primary response gene 88)

209 ive bacteria Vibrio cholerae, induces TLR1/2-MyD88-NF-kappaB-dependent proinflammatory cytokine produ

210 The MyD88/NF-kappaB signaling pathway was found to be critic

211 he activation of NLRP3 inflammasome and TLR4/MyD88/NF-kappaB signaling pathways, and suppressed the p

212 led to upregulate feedback inhibitors of the MyD88-nuclear factor kappaB signaling pathway.

213 Adipocyte-specific MyD88 or IRAK2 deficiency reduced high-fat-diet-induced

214 Deletion of Myd88 or Rorc in Treg cells abrogated protection by bact

215 ecognition receptor (PRR) pathways involving MyD88 or STING constitute a first-line defense against i

216 IF but dispensable for pathways dependent on MyD88 or STING.

217 NKT cells, we used mice deficient for either MyD88 or the IL-12Rbeta2 in the T cell lineage.

218 , but did not affect parasite replication in Myd88(-/-) or Unc93b1(-/-) macrophages.

219 myeloid differentiation primary response 88 (MyD88) or TIR-domain-containing adapter-inducing interfe

220 anti-chromatin Ab, into mice lacking Fcer1g, Myd88, or both and studied the extrafollicular plasmabla

221 pients lacking mature IL-1beta, IL-6, IL-1R, MyD88, or IL-6R impair CD4(+) and CD8(+) T cell recovery

222 defining DLBCL molecular subtypes and posit MYD88/p100 signaling as a regulator for B-cell activatio

223 on macrophages, leading to activation of the MyD88 pathway and TNF-alpha production.

224 ndings establish the T-cell intrinsic IL-18R/MyD88 pathway as a crucial element for induction of cogn

225 ticularly TLR4, and its downstream-signaling MyD88 pathway play an important role in regulating myelo

226 ated macrophages (TAMs) through the TLR2 and MyD88 pathway, and recruits p62 to activate the autophag

227 R4-dependent cytokine production through the MyD88 pathway, independently of TRIF.

228 not of IL-1R, phenocopied the absence of the MyD88 pathway, indicating that IL-18R is a critical MyD8

229 ncreased expression is dependent on an IL-1R-MyD88 pathway.

230 Cell-intrinsic Notch2 and TLR7-Myd88 pathways independently and synergistically promote

231 and SYK crosstalk as a critical regulator of MyD88 post-translational modifications and IL-1-driven i

232 SYK as a critical kinase that phosphorylates MyD88, promoted MyD88-dependent signaling and mediates d

233 MyD88 protein levels are increased during in vitro myoge

234 by genetic alterations of BCL2, NOTCH2, and MYD88 recapitulated recent studies showing good, interme

235 Ablation of MyD88 reduces myofiber size during muscle regeneration,

236 MyD88 regulates non-canonical NF-kappaB and canonical Wn

237 ional T cells (Tcons) with wild-type (WT) or MyD88(-/-) regulatory T cells (Tregs) lowered aGVHD seve

238 Given these observations, CD8alpha:MyD88 represents a unique and versatile approach to help

239 We also demonstrate that CRISPR-mediated Myd88 repression can act as a prophylactic measure again

240 Myd88 repression leads to a decrease in immunoglobulin G

241 WT mice, however, indicating a role for the MyD88 response in facilitating the primary lung infectio

242 Thus, commensals activate a MyD88/ROR-gammat pathway in nascent Treg cells to protec

243 erial sepsis via Toll-like receptor 4 (TLR4)/MyD88 sensing of lipopolysaccharides.

244 conclusion, activation of TAK-1 by the TLR-4/MyD88 signal transduction pathway and MLCK by NF-kappaB

245 naling, several, including that encoding the MyD88 signaling adaptor, also produce alternative splice

246 ing multitypic interactions with the MAL and MyD88 signaling adaptors.

247 n pericytes or pharmacological inhibition of MyD88 signaling by an IRAK4 inhibitor in vivo protected

248 is, at least in part, via inhibition of TLR4/MyD88 signaling cascade as well as inactivation of NLRP3

249 In vitro, baicalein down-regulated the TLR4/MyD88 signaling cascades (NF-kappaB and MAPKs) in lipopo

250 ia, in which they required endosomal TLR and MyD88 signaling for differentiation.

251 a suggest that Treg suppression from lack of MyD88 signaling in donor Tcons during alloreactivity use

252 To probe IRAK/MYD88 signaling in PEL, we employed CRISPR/Cas9 technolo

253 Alteration of the microbiome alters TLR7-MyD88 signaling in plasmacytoid dendritic cells (pDCs) a

254 hat this tonic IL-12 production requires TLR-MyD88 signaling independent of foreign agonists, and is

255 Here, we demonstrated that T-cell intrinsic MyD88 signaling is required for proliferation, protectio

256 Collectively these data demonstrate MyD88 signaling mediates early inflammatory responses in

257 d dendritic cells and monocytes via TLR7 and MyD88 signaling to protect from alphavirus dissemination

258 role for myeloid differentiation factor 88 (MyD88) signaling in supporting remyelination by promotin

259 lammation in the murine lung via a TLR2/TLR4/MyD88-signaling pathway.

260 n Ab production by blocking both BCR and TLR-MyD88 signals.

261 used by another RNA regulatory mechanism, 2) MyD88 splicing is regulated by both the MyD88- and TRIF-

262 endent arms of the TLR signaling pathway, 3) MyD88 splicing is regulated by the NF-kappaB transcripti

263 RNAscope confirmed focal infection in MyD88(-/-), STAT1(-/-), and CCR6(-/-) mice but was negat

264 However, unlike MyD88, STING also contributed to viral control in non-he

265 the NOTCH2 subtype and poor prognosis in the MYD88 subtype.

266 otype with what we observed when using donor MyD88(-/-) Tcons.

267 id differentiation primary response gene 88 (MyD88), the common adaptor for toll-like receptor (TLR)

268 In macrophages lacking MyD88, there is minimal NF-kappaB translocation to the n

269 C57BL/6 (control), Myd88(-/-), Ticam1(-/-), and Il15(-/-) mice were placed

270 transcription factors and involved elevated MYD88/TLR pathway activity.

271 R2 signaling competence, leading to impaired MyD88-TLR2 assembly, reduced phosphorylation of IRAK-1,

272 We also confirmed that Myd88(-/-), Tlr3/7/9(-/-), and Unc93b1(-/-) cells were h

273 dy, we generated Mer(-/-) mice with a global MyD88, TLR7, or TLR9 deficiency and cell type-specific M

274 bitor ibrutinib and promotes assembly of the MYD88-TLR9-BCR (My-T-BCR) supercomplex, which initiates

275 R753Q TLR2 displayed reduced recruitment of MyD88 to TLR2, decreased NF-kappaB activation, and impai

276 tein by linking CD8alpha and MyD88 (CD8alpha:MyD88) to enhance CD8(+) T-cell responses to weakly immu

277 induced alternative pre-mRNA splicing of the MyD88 transcript in murine macrophages.

278 The ability to control Myd88 transcript levels using a CRISPR-based synthetic r

279 n regulating splicing indirectly by altering MyD88 transcription.

280 acrophages from WT, MyD88 (-/-), Trif (-/-), MyD88 (-/-) Trif (-/-), MK2 (-/-), and Zfp36 (-/-) mice

281 have stimulated murine macrophages from WT, MyD88 (-/-), Trif (-/-), MyD88 (-/-) Trif (-/-), MK2 (-/

282 CRs) in the TI B cell immunity, we here used MyD88-, TRIF-, and alpha-galactosyltransferase-deficient

283 The utilization of macrophages derived from MyD88-, TRIF-, Toll-like receptor 2 (TLR2)-, TLR4-, and

284 innate pathogen sensing mechanisms, we show MYD88/TRIF, Caspase-1/Caspase-11 inflammasome, and NOD1/

285 ox 1 (HMGB1) release activates the host TLR4/MyD88/type I interferon pathway and Batf3 dendritic cell

286 SHP1 and SYK-dependent counterregulation of MyD88 tyrosine phosphorylation, we have demonstrated tha

287 athway, indicating that IL-18R is a critical MyD88-upstream pathway involved in the establishment of

288 Herein, we contrasted anti-viral effects of MyD88 versus STING in distinct cell types that are infec

289 ains and ubiquitylation of IRAK1, IRAK4, and MyD88 was abolished in TRAF6/Pellino1/Pellino2 triple-kn

290 to the expression of serum IFN-beta, whereas MyD88 was not.

291 id differentiation primary response gene 88 (MyD88) was increased in skeletal muscle in a Lewis lung

292 hritis in A20(ZF7) mice required T cells and MyD88, was exquisitely sensitive to tumor necrosis facto

293 IL1 receptor or the receptor adapter protein MyD88, were not protected from tumor-induced decreases i

294 endent of myeloid differentiation factor 88 (MyD88), which is the only known signaling adaptor for TL

295 myeloid differentiation primary response 88 (MyD88), which signals through NF-kappaB, led to an accel

296 patients genetically deficient for IRAK4 or MYD88, which mediate the function of Toll-like receptors

297 Patients with wild-type MYD88 WM show an increased risk of transformation and de

298 nd myeloid cells isolated from Tlr4(-/-) and Myd88 (-/-) wounds demonstrated decreased inflammatory c

299 Conversely, four patients who had MYD88(WT) disease showed no major responses.

300 In patients with MYD88(WT), the median PFS was 0.4 years (P < .01 for thr